Literature DB >> 29698937

Differences in Race and Ethnicity in Muscular Dystrophy Mortality Rates for Males under 40 Years of Age, 2006-2015.

Deborah C Salzberg1, Joshua R Mann2, Suzanne McDermott1.   

Abstract

BACKGROUND/AIMS: Duchenne Muscular Dystrophy (DMD) has childhood onset, primarily affects males, and is usually fatal before the age of 40 years. Previous studies have indicated that this X-linked condition is more prevalent in whites than in blacks, but those were based on active surveillance, and limited to smaller populations and younger ages.
METHODS: US death data were used to calculate mortality rates by race and ethnicity, with MD as either the underlying or multiple cause of death (MCD). Poisson approximation was used for confidence intervals; chi-square was used to compare rates.
RESULTS: From 2006 to 2015, there were 3,256 deaths in males <40 years with MD as MCD, and 71% of these were aged 15-29 years. For whites, the average annual death rate was 0.43/100,000, which was significantly higher (p < 0.0001) that that of blacks (0.28), American Indian/Alaska Natives (0.20), and Asian/Pacific Islanders (0.21). The rate for non-Hispanic whites (0.46) was significantly higher (p < 0.0001) than the rates for Hispanic whites (0.31), Hispanic blacks (0.07), and non-Hispanic blacks (0.29).
CONCLUSION: Since DMD is the primary cause of deaths in young males with MD, mortality rates are a reasonable proxy for the relative difference in racial prevalence. It appears that DMD is significantly more common in white males than in males of other races.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  DBMD; Duchenne; Mortality rate; Muscular dystrophy; Racial differences

Mesh:

Year:  2018        PMID: 29698937     DOI: 10.1159/000488244

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

1.  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.

Authors:  Daniela J Conrado; Jane Larkindale; Alexander Berg; Micki Hill; Jackson Burton; Keith R Abrams; Richard T Abresch; Abby Bronson; Douglass Chapman; Michael Crowther; Tina Duong; Heather Gordish-Dressman; Lutz Harnisch; Erik Henricson; Sarah Kim; Craig M McDonald; Stephan Schmidt; Camille Vong; Xiaoxing Wang; Brenda L Wong; Florence Yong; Klaus Romero
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-05-24       Impact factor: 2.745

2.  Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Pangaja Paramsothy; Yinding Wang; Bo Cai; Kristin M Conway; Nicholas E Johnson; Shree Pandya; Emma Ciafaloni; Katherine D Mathews; Paul A Romitti; James F Howard; Catharine Riley
Journal:  Neuromuscul Disord       Date:  2022-04-30       Impact factor: 3.538

Review 3.  Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.

Authors:  Mark R Cullen; Adina R Lemeshow; Leo J Russo; David M Barnes; Yaa Ababio; Aida Habtezion
Journal:  Healthcare (Basel)       Date:  2022-03-23

Review 4.  The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.

Authors:  Shelagh M Szabo; Renna M Salhany; Alison Deighton; Meagan Harwood; Jean Mah; Katherine L Gooch
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

5.  Epidemiological Characteristics of Infectious Diseases Among Travelers Between China and Foreign Countries Before and During the Early Stage of the COVID-19 Pandemic.

Authors:  Zheng Luo; Wei Wang; Yibo Ding; Jiaxin Xie; Jinhua Lu; Wen Xue; Yichen Chen; Ruiping Wang; Xiaopan Li; Lile Wu
Journal:  Front Public Health       Date:  2021-11-03

6.  A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain.

Authors:  Laura Llamosas-Falcón; Germán Sánchez-Díaz; Elisa Gallego; Ana Villaverde-Hueso; Greta Arias-Merino; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.